White label – Pompe disease - ClinicalTrials.eu

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Recruiting

3 1
Investigated Diseases:
- Narcolepsy
Investigated Drugs:
- Alks 2680
Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Recruiting

3 1 1
Investigated Drugs:
- Bendamustine Hydrochloride
- Rituximab
A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Recruiting

3 1 1 1
Investigated Diseases:
- Factor VIII deficiency
Investigated Drugs:
- Ro7589655
- Simoctocog Alfa
+3
Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Recruiting

3 1 1 1
Investigated Diseases:
- Factor VIII deficiency
Investigated Drugs:
- Emicizumab
- Ro7589655
+5
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

Recruiting

2 1 1
Investigated Diseases:
- Glycogen storage disease type II
Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Recruiting

3 1 1
Investigated Drugs:
+1
Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

Recruiting

2 1 1 1
Investigated Drugs:
- Asciminib Hydrochloride
- Ponatinib
Study of FLUDEOXYGLUCOSE (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

Recruiting

3 1 1 1
Investigated Diseases:
- Post-acute COVID-19 syndrome
Investigated Drugs:
- Fludeoxyglucose (18F)
Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

Recruiting

2 1
Investigated Drugs:
- Povetacicept
Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

Recruiting

2 1
Investigated Diseases:
- Vitiligo

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies